Effect of Inhaled Corticosteroids on Markers of Pulmonary Inflammation and Lung Maturation in Preterm Infants with Evolving Chronic Lung Disease

Journal of the American Osteopathic Association

Volumn 104, Issue 3, 2004, Pages 114-120

  Parikh, Nehal A ^a,b,d   Locke, Robert G ^a   Chidekel, Aaron ^a   Leef, Kathleen H ^a   Emberger, John ^a   Paul, David A ^a   Stefano, John L ^a,c  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b Neonatal/Perinatal Medicine   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY PRESSURE; APGAR SCORE; ARTICLE; BIRTH WEIGHT; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; GESTATIONAL AGE; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; LUNG DEVELOPMENT; LUNG FUNCTION; METERED DOSE INHALER; NEWBORN; PREMATURITY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; BECLOMETHASONE; BIOLOGICAL MARKERS; CHRONIC DISEASE; CYTOKINES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; LUNG; LUNG DISEASES; PNEUMONIA;

EID: 1642546508     PISSN: 00986151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Stevenson DK, Wright LL, Lemons JA, Oh W, Korones SB, Papile LA, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol. 1998;179(6 Pt 1):1632-1639.
2. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm [review]. Early Hum Dev. 1998;53:81-94.
3. Ozdemir A, Brown MA, Morgan WJ. Markers and mediators of inflammation in neonatal lung disease [review]. Pediatr Pulmonol. 1997;23:292-306.
4. Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia [review]. Pediatr Pulmonol. 1995;19:371-378.
5. Watterberg KL, Gerdes JS, Cook KL. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. Pediatr Res. 2001;50:190-195. Available at: http://www.pedresearch.org/cgi/content/full/50/2/190. Accessed February 19, 2004.
6. Korte C, Styne D, Merritt TA, Mayes D, Wertz A, Helbock HJ. Adrenocortical function in the very low birth weight infant: improved testing sensitivity and association with neonatal outcome. J Pediatr. 1996;128:257-263.
7. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics. 1995;95:120-125.
8. Shaw NJ, Gill AB, Weindling AM, Cooke RW. The changing incidence of chronic lung disease. Health Trends. 1993;25:50-53.
9. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al for the National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001;344:95-101.
10. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs [review]. BMC Pediatr. 2001;1:1 Epub 2001 Feb 27. Available at: http//www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid= 11248841. Accessed February 19, 2004.
11. Ng PC, Fok TF, Wong GWK, Lam CWK, Lee CH, Wong MY, et al. Pituitaryadrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab. 1998;83:2390-2393. Available at: http//jcem.endojournals.org/cgi/content/full/83/7/2390. Accessed February 19, 2004.
12. Cole CH, Colton T, Shah BL, Abbasi S, MacKinnon BL, Demissie S, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med. 1999;340:1005-1010.
13. Fok TF, Lam K, Dolovich M, Ng PC, Wong W, Cheung KL, et al. Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1999;80:F203-F208. Available at:http//adc.bmjjournals.com/cgi/content/full/ fetalneonatal%3b80/3/F203. Accessed February 19, 2004.
14. Liu EA, Heldt GP. A trial of the safety of inhaled beclomethasone in ventilator-treated neonates. J Pediatr. 1996;129:154-156.
15. Zimmerman JJ, Gabbert D, Shivpuri C, Kayata S, Ciesielski W, Miller J, et al. Meter-dosed, inhaled beclomethasone attenuates bronchoalveolar oxyradical inflammation in premature infants at risk for bronchopulmonary dysplasia. Am J Perinatol. 1998;15:567-576.
16. LaForce WR, Brudno DS. Controlled trial of beclomethasone dipropionate by nebulization in oxygen- and ventilator-dependant infants. J Pediatr. 1993;122:285-288.
17. O'Callaghan C, Hardy J, Stammers J, Stephenson TJ, Hull D. Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model. Arch Dis Child. 1992;67(1 Spec No):20-24.
18. Cameron D, Clay M, Silverman M. Evaluation of nebulizers for use in neonatal ventilator circuits. Crit Care Med. 1990;18:866-870.
19. Locke R, Greenspan JS, Shaffer TH, Rubenstein SD, Wolfson MR. Effect of nasal CPAP on thoracoabdominal motion in neonates with respiratory insufficiency. Pediatr Pulmonol. 1991;11:259-264.
20. Bayley N. Manual for the Bayley Scales of Infant Development (BSID II). 2nd ed. San Antonio, Tex: Psychological Corporation; 1993.
21. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83:F177-F181. Available at: http://adc.bmjjournals.con/cgi/content/full/fetalneonatal%3b83/3/F177. Accessed February 19, 2004.
22. Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001;107:217-221.
23. Groneck P, Goetze-Speer B, Speer CP. Effects of inhaled bedomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease. Pediatr Pulmonol. 1999;27:383-387.
24. Merz U, Kusenbach G, Hausler M, Peschgens T, Hornchen H. Inhaled budesonide in ventilator-dependant preterm infants: A randomized, double-blind pilot study. Biol Neonate. 1999;75:46-53.
25. Gupta GK, Cole CH, Abbasi S, Demissie S, Njinimbam C, Nielsen HC, et al. Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol. 2000;30:275-281.
26. Halliday HL, Patterson CC, Halahakoon CW, for the European Multicenter Steroid Study Group. A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics. 2001;107:232-240.
27. Jobe AJ. The new BPD: an arrest of lung development [review]. Pediatr Res. 1999;46:641-643.
28. Kotecha S, Wilson L, Wangoo A, Silverman M, Shaw RJ. Increase in interleukin (IL)-1β and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res. 1996;40:250-256.
29. Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia [review]. Current issues. Pediatr Clin North Am. 1994;41:277-315.
30. Ozdemir A, Brown MA, Morgan WJ. Markers and mediators of inflammation in neonatal lung disease [review]. Pediatr Pulmonol. 1997:23:292-306.
31. Emerson GA, Bry K, Hallman M, Jobe AH, Wada N, Ervin MG, Ikegami M. Intra-amniotic interleukin-1α treatment alters postnatal adaptation in premature lambs. Biol Neonate. 1997,72(6):370-379.
32. Bry K, Lappalainen U, Hallman M. Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth. J Clin Invest. 1997;99:2992-2999. Available at: http//www.jci.org/cgi/content/full/99/12/2992. Accessed February 19, 2004.
33. Hybertson BM, Lee YM, Cho HG, Cho OJ, Repine JE. Alveolar type II cell abnormalities and peroxide formation in lungs of rats given IL-1 intratracheally. Inflammation. 2000;24:289-303.
34. Jobe AH. Glucocorticoids in perinatal medicine: misguided rockets? J Pediatr. 2000;137:1-3.
35. Finer NN, Craft A, Vaucher YE, Clark RH, Sola A. Postnatal steroids: short-term gain, long-term pain [review]? J Pediatr. 2000;137:9-13.
36. Thebaud B, Lacaze-Masmonteil T, Watterberg K. Postnatal glucocorticoids in very preterm infants: "The good, the bad, and the ugly?" Pediatrics. 2001:107;413-415.
37. Halliday HL, Ehrenkranz RA. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants [review]. Cochrane Database Syst Rev. 2001;1:CD001146. Update in: Cochrane Database Syst Rev. 2003;1:CD001146.
38. Halliday HL, Ehrenkranz RA. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants [review]. Cochrane Database Syst Rev. 2001;1:CD001146. Update in: Cochrane Database Syst Rev. 2003;1:CD001146.
39. Halliday HL, Ehrenkranz RA. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants [review]. Cochrane Database Syst Rev. 2001;1:CD001144. Update in: Cochrane Database Syst Rev. 2003;1:CD001144.
40. Halliday HL, Ehrenkranz RA. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants [review]. Cochrane Database Syst Rev. 2001;1:CD001144. Update in: Cochrane Database Syst Rev. 2003;1:CD001144.
41. Shah V, Ohlsson A, Halliday HL, Dunn MS Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates [review]. Cochrane Database Syst Rev. 2000;2:CD001969.
42. Denjean A, Paris-Llado J, Zupan V, Debillon T, Kieffer F, Magny JF, et al. Inhaled salbutamol and beclomethasone for preventing bronco-pulmonary dysplasia: a randomised double-blind study. EurJ Pediatr. 1998;157:926-931.
43. Lister P, Iles R, Shaw B, Ducharme F. Inhaled steroids for neonatal chronic lung disease [review]. Cochrane Database Syst Rev. 2000;3:CD002311.
44. Cole CH, Mitchell JP, Foley M, Nagel M, Doyle CC, Bates SL. Comparison of hydrofluoroalkane (HFA)- and chlorofluorocarbon (CFC)-inhaled glucocorticoid formulations for aerosol particle size and delivery efficiency in a neonatal model [poster board 345]. Ped Res. 2002;51:356A. 2071.
45. Cole CH, Shah B, Abbasi S, Demissie S, MacKinnon B, Colton T, et al. Adrenal function in premature infants during inhaled beclomethasone therapy. J Pediatr. 1999;135:65-70.
46. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989;320:1505-1510.
47. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG 3rd, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104(1 Pt 1):15-21.
48. Fitzhardinge PM, Eisen A, Lejtenyi C, Metrakos K, Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics. 1974;53:877-883.
49. Fetus and Newborn Committee. AAP. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109:330-338.
50. The HIFI Study Group. High-frequency oscillatory ventilation compared with conventional mechanical ventilation in the treatment of respiratory failure in preterm infants. N Engl J Med. 1989;320:88-93.
51. HiFO Study Group. Randomized study of high-frequency oscillatory ventilation in infants with severe respiratory distress syndrome. J Pediatr. 1993;122:609-619.
52. Ogawa Y, Miyasaka K, Kawano T, Imura S, Inukai K, Okuyama K, et al. A multicenter randomized trial of high frequency oscillatory ventilation as compared with conventional mechanical ventilation in preterm infants with respiratory failure. Early Hum Dev. 1993;32:1-10.
53. Rettwitz-Volk W, Veldman A, Roth B, Vierzig A, Kachel W, Varnholt V, et al. A prospective, randomized, multicenter trial of high-frequency oscillatory ventilation compared with conventional ventilation in preterm infants with respiratory distress syndrome receiving surfactant. J Pediatr. 1998;132:249-254.
54. Thome U, Kossel H, Lipowsky G, Porz F, Furste HO, Genzel-Boroviczeny O, et al. Randomized comparison of high-frequency ventilation with high-rate intermittent positive pressure ventilation in preterm infants with respiratory failure. J Pediatr. 1999;135:39-46.
55. Moriette G, Paris-Llado J, Walti H, Escande B, Magny JF, Cambonie G, et al. Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome. Pediatrics. 2001;107:363-372.
56. Gerstmann DR, Minton SD, Stoddard RA, Meredith KS, Monaco F, Bertrand JM, et al. The Provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome. Pediatrics. 1996;98(6 Pt 1):1044-1057.
57. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT, for the Neonatal Ventilation Study Group. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med. 2002;347:643-652.
58. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, et al, for the United Kingdom Oscillation Study Group. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med. 2002;347:633-642.
59. Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S, et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet. 1999;354:1061-1065.
60. Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child Fetal Neonatal Ed. 1997;77:F185-F1890. Available at: http://adc.bmjjournals.com/cgi/content/full/fetalneonatal%3b77/3/F185. Accessed February 19, 2004.
61. The Franco-Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet. 1999;354:1066-1071. Erratum in: Lancet. 1999;354:1826.
62. The Franco-Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet. 1999;354:1066-1071. Erratum in: Lancet. 1999;354:1826.